Publication: Indinavir/ritonavir remains an important component of HAART for the treatment of HIV/AIDS, particularly in resource-limited settings
Issued Date
2007-06-01
Resource Type
ISSN
17425255
Other identifier(s)
2-s2.0-34548273143
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Expert Opinion on Drug Metabolism and Toxicology. Vol.3, No.3 (2007), 347-361
Suggested Citation
Tim R. Cressey, Plipat Nottasorn, Federica Fregonese, Kulkanya Chokephaibulkit Indinavir/ritonavir remains an important component of HAART for the treatment of HIV/AIDS, particularly in resource-limited settings. Expert Opinion on Drug Metabolism and Toxicology. Vol.3, No.3 (2007), 347-361. doi:10.1517/17425255.3.3.347 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/25102
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Indinavir/ritonavir remains an important component of HAART for the treatment of HIV/AIDS, particularly in resource-limited settings
Abstract
For over a decade, indinavir has been approved for the treatment of HIV/ AIDS; however, following the introduction of new protease inhibitors (PIs) with improved safety and pharmacologic profiles, its use in developed countries has become almost obsolete. In contrast, in resource-limited settings where the majority of people living with HIV/ AIDS reside, indinavir is part of the most affordable PI-based highly active antiretroviral treatment regimen. A major drawback of indinavir use is renal toxicity, but low-dose indinavir plus ritonavir (400/100 mg) twice daily is both efficacious and tolerable. Similar low dosing levels in children have also proven successful, but data in pregnant women remains limited. Due to its low cost and proven efficacy indinavir remains a key component of HIV/AIDS treatment in resource-limited settings. © 2007 Informa UK Ltd.